Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Their website shows otherwise Atlanta as they are still accepting inquiries/bids. This image shows their 4 core businesses.
https://sintx.com/applications/ceramic-armor/
Since they have not exited the Armor market, they'll either be manufacturing at the TA&T facility that produces Spinel Armor or outsourcing it which seems like a silly option when they already have armor producting facility. As i said previously, streamlining operations suggests getting rid of redundancies. They had two armor facilities, one of which didnt produce anything anyways, and thus it makes sense to shut it down and move production to TA&T. It is still odd they didnt just indicate that unless it has to due with the strategic opportunities they are exploring.
Normally a company would say that they are exploring which direction they are going to go in regards to a business unit and for some reason Sintx has not done that. Like we are exploring using our TA&T subsidiary for armor production or are looking at outsourcing the manufacturing. Something akin to that. The fact that they give no indication is I have speculated that is because it may be part of ongoing negations between Sintx and one of the partners I believe it has, NP Aerospace. It is worth mentioning that Ascendiant Capital, whom Sintx used to acquire armor assets and TA&T, is being used to help Sintx with it exploring strategic opportunities. Further suggesting that what is going on is connected to TA&T facility and/or armor. I posted about Ascendiants involvement on Sintx acquisitions of Armor & TA&T here. Outside of a Sockpuppet bot, posters here will not discuss NP Aerospace. More info on how to recognize Sockpuppet Bot in section 3 of this post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175020737
Quote Sources:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224031644/form10-q.htm
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities
https://www.techassess.com/
=======================================
I was disappointed with todays webinar because i had hoped to hear about something healthcare related. Also, and i may have missed this, but i didnt catch much in the way of innovation. Progress yes, but innovation i missed. The webinar seemed liked it was more about educating interested customers in the industrial space. Nice to see in regards to Aerospace applications but not what i was hoping for.
=======================================
Can tin foil hats be paired with SINT products to prevent brain cancers?
Dick Van Dyke's tooth is the smoking gun, and proof EM interacts with dental implants !
The 10Q comment was in specific reference to the decision to shutdown the armor plant.
Yeah, if you think a lead balloon can fly, then Sintx technologies is a masterpiece. It's like trying to find a needle in a haystack, except the haystack is a desert and the needle is a ghost."
Yes, but if you want to read what's not there, you'll come to a different conclusion. That's why Sint is a rocketing success and although the rocket seems to continually point downwards, it's still a success!
here are some potential reasons why some might speculate that Sintx is considering exiting the armor market:
Streamlining Operations: The statement in the August 10Q about streamlining operations and focusing on core business areas could suggest that Sintx is reassessing its portfolio and considering divesting from businesses that are not considered core to its long-term strategy.
Market Conditions: The armor market may be facing challenges such as decreased demand, increased competition, or regulatory changes that make it less attractive for Sintx.
Strategic Focus: Sintx may be shifting its focus towards other business areas that it believes have greater growth potential or align more closely with its overall strategic goals.
Financial Performance: If the armor business is underperforming financially, Sintx may be considering exiting it to improve its overall financial health.
Webinar Focus: The webinar's focus on 3D printing for healthcare, aerospace, and defense does not necessarily imply a shift in armor manufacturing. It's possible that Sintx is simply highlighting its progress in these areas while maintaining its existing armor operations.
Streamlining Operations: While streamlining operations can sometimes involve the consolidation of facilities, it doesn't automatically mean that one facility is being abandoned. Sintx might be optimizing its production processes or reallocating resources to improve efficiency without completely eliminating armor manufacturing.
TA&T and Armor: The fact that TA&T already produces ceramic armor plates doesn't automatically mean that Sintx is moving its entire armor production there. It could be that Sintx is simply expanding its capabilities or exploring new opportunities within the armor market.
NP Aerospace: The absence of specific information about Sintx's plans regarding NP Aerospace doesn't necessarily support the theory of ongoing negotiations. Companies often keep their strategic plans confidential, especially when they involve partnerships or acquisitions.
Scientific and Factual Considerations:
Financial Reports: Sintx's financial reports should provide clear information about its business segments, including armor. If there were any significant changes in armor operations, they would likely be reflected in these reports.
Industry Trends: Analyzing industry trends in armor manufacturing can help determine if Sintx's actions are consistent with market developments. If there were significant shifts in demand or technology, it might explain any changes in Sintx's operations.
Public Statements: Reviewing public statements from Sintx's executives can provide clues about their intentions. If they had made any specific announcements about armor manufacturing or NP Aerospace, these would likely be widely reported.
Conclusion:
Based on the available information, the conspiracy theory that Sintx is moving its armor manufacturing to TA&T and negotiating with NP Aerospace lacks sufficient evidence. While there may be some indications that support the theory, such as the streamlining of operations and the involvement of TA&T, these factors alone do not definitively prove the claim. To definitively debunk or confirm the theory, more information would be needed, such as detailed financial reports, public statements from Sintx's executives, or specific evidence of negotiations with NP Aerospace.
First off i do not know why Noneya on ST is treating tomorrows Webinar with Prodways & TCT working as moderator as a Sintx conference call, but obviously its not; someone should correct him on ST because hes purposefully being misleading. The Webinar is only covering what sort of progress theyve made with 3D printing for healthcare, aerospace, and defense.
Having said that, the statement of streamlining operations is what supports the idea they have moved armor manufacturing to TA&T as they technically had two facilities that could produce armor making one of them redundant. Furthermore armor is part of their 4 core businesses under Technical. Its all over that 10Q you just referenced and the companies website. Lastly, they did not in fact say they were exiting the armor market. Since they did not say they were exiting armor market, the fact that armor market is one of their core businesses, the fact they had two armor producing facilities, & moved their quality management system to TA&T, all suggests they are going to produce armor at the TA&T buildings that already manufactures ceramic armor plates. Also if they were exiting the armor market they would have specified they were, they would not made a statement that is vague and left open to interpretation.
Also worth noting that you and Joe are not even addressing the NP Aerospace portion of my post so i'll repost it and see if you guys wish to comment about NP Aerospace and Sintx.
I'll add its odd that they do not specify what direction they are going with armor. Normally a company would say that they are exploring which direction they are going to go in regards to a business unit and for some reason Sintx has not done that. Like we are exploring using our TA&T subsidiary for armor production or are looking at outsourcing the manufacturing. Something akin to that. The fact that they give no indication is I have speculated that is because it may be part of ongoing negations between Sintx and one of the partners I believe it has, NP Aerospace. It is worth mentioning that Ascendiant Capital, whom Sintx used to acquire armor assets and TA&T, is being used to help Sintx with it exploring strategic opportunities. Further suggesting that what is going on is connected to TA&T facility and/or armor. I posted about Ascendiants involvement on Sintx acquisitions of Armor & TA&T here. Outside of a Sockpuppet bot, posters here will not discuss NP Aerospace. More info on how to recognize Sockpuppet Bot in section 3 of this post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175020737
Quote Sources:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224031644/form10-q.htm
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities
https://www.techassess.com/
========================================
Joe,
Its unlikely they are lying. However withholding information, could be warranted here, as its been their MO since IPO like when certain personnel had ties to Zimmer and that wasnt disclosed on their IPO paperwork in 2014 but was in 2007. It is possible that the manufacturing and testing occurred before Oct 2023 as they do not specify when it occurred. That said, for what purpose do you think they implemented their quality control system at TA&T? That suggests they intend on using TA&T for manufacturing. What might that be if not armor?
========================================
from the August 10Q:
"This decision was made to streamline operations and focus on core business areas that align with the Company’s long-term strategic goals."
Ths sounds like an exit from the armor business to me.
Debunking the Sintx Armor Conspiracy Theory
The theory suggests Sintx is secretly moving armor production to TA&T without disclosing it. Let's analyze the claims logically:
Shifting Production is Common: Companies routinely close inefficient facilities and move production elsewhere. Shutting down the Salt Lake facility doesn't mean Sintx is exiting armor entirely.
Testing Doesn't Require Full Production: Sintx could have manufactured test armor at a smaller pilot facility, with outside contractors, or even at the Salt Lake facility before the furnace malfunction.
TA&T Capabilities Don't Necessarily Align: Just because TA&T makes a different type of ceramic (spinel) doesn't guarantee they can produce Sintx's specific armor (BoroShock or DuraShock).
COO Relocation Doesn't Confirm Armor Move: The COO's relocation could be for various reasons unrelated to armor production, such as managing TA&T's core business.
Disclosure Requirements: Public companies like Sintx have reporting obligations. If there's a material change in their business, like exiting armor entirely, they'd be legally bound to disclose it.
Occam's Razor: The simpler explanation is often more likely. Perhaps Sintx is genuinely exploring strategic options, not hiding a secret armor move.
Here's a more logical explanation:
Sintx shut down the Salt Lake facility due to a malfunctioning furnace, making production there impractical.
They're exploring alternative production options, which could include TA&T's facilities or outsourcing to a third party.
They haven't publicly announced their plans because they haven't finalized them.
This scenario doesn't require elaborate conspiracies or sockpuppet accounts. It's simply a company adapting to challenges.
Or....the company could just simply be lying. Wouldn't be the first time. Or, I guess a slight possibility that the "success" was BEFORE Oct 2023?
On Sintx Q2 10Q Sintx indicated it had given up on its armor facility in Salt Lake but did not in fact say it was exiting the armor market in the 10Q or any following press release. Looking over a previous press release earlier this year, it was indicated that the company had manufactured and successfully tested armor for personal and vehicle applications. How could that be if the Salt Lake facility has been completely shut down since October 2023? That means only one thing, that they manufactured the armor at a different facility. The only facility that has the ability to manufacture armor that I am aware of is TA&T in Maryland where it recently expanded its Quality Management System to which was likely why the COO relocated there. TA&T uses two buildings and the second building is used for spinel ceramic armor production per its website. Thus Sintx must be moving armor production there but for some reason it has not disclosed this; it also has not indicated otherwise.
Aug 13th
June 18th, 2024
Debunking the Silicon Nitride Hype: A Scientific Perspective
Claim 1: Bacteriostatic Behavior of Silicon Nitride
While silicon nitride (Si3N4) has shown promising antibacterial properties, the mechanisms behind its bacteriostatic behavior are complex and not fully understood. While surface effects like submicron-topography, negative charging, and chemical interactions may play a role, it's important to note that the specific mechanisms of action can vary depending on the surface treatment and the type of bacteria.
Claim 2: Antifungal Activity of Polymethyl Methacrylate/Si3N4 Composites
While the study demonstrates the antifungal activity of Si3N4-containing PMMA composites against Candida albicans, it's important to consider the limitations of the study. The results may not be generalizable to other fungal species or clinical settings. Additionally, the long-term efficacy and biocompatibility of these composites in vivo need to be further evaluated.
Claim 3: Silicon Nitride as a Biomedical Material
While silicon nitride offers several advantages as a biomedical material, such as high strength, bio-responsiveness, and favorable imaging properties, it's important to acknowledge its limitations. The brittleness and high manufacturing cost of Si3N4 can pose challenges for its widespread adoption in clinical applications. Furthermore, while Si3N4 has shown promise in orthopedic implants, its suitability for other biomedical applications, such as dental implants or drug delivery, may require further research and development.
Overall Assessment
While silicon nitride shows potential as a biomedical material, it's important to approach the claims with a critical eye. The mechanisms underlying its antibacterial and antifungal properties are complex and require further investigation. Additionally, the limitations and challenges associated with its use in clinical applications must be carefully considered. While Si3N4 offers promising possibilities, more research is needed to fully understand its potential and limitations.
Bacteriostatic behavior of surface modulated silicon nitride in comparison to polyetheretherketone and titanium
Antifungal activity of polymethyl methacrylate/Si3N4 composites against Candida albicans
Silicon Nitride as a Biomedical Material: An Overview
The Claim: Chronic wounds are primarily caused by fungi, and silicon nitride is a miraculous material that can eliminate these fungal infections.
The Reality: While fungi can certainly play a role in some chronic wounds, especially those with poor circulation or compromised immune systems, bacteria are typically the primary culprits.
Key Scientific Points:
Microbial Composition: Studies have consistently shown that bacteria are the predominant microorganisms found in chronic wounds. While fungi can be present, their abundance and contribution to wound pathology vary depending on factors such as wound type, location, and the individual's health status.
Fungal Role: Fungi can contribute to chronic wounds by causing infections, creating a favorable environment for bacterial growth, and hindering the healing process. However, they are often secondary to bacterial infections.
Silicon Nitride's Limitations: While silicon nitride has shown antibacterial properties, its effectiveness against fungi is limited. While it may help to reduce the overall microbial burden in a wound, it is unlikely to completely eliminate fungal infections on its own.
Complex Wound Healing: Chronic wound healing is a complex process involving various factors, including blood flow, immune function, and the presence of certain growth factors. Simply targeting microorganisms may not be sufficient to address all the underlying causes of chronic wounds.
Conclusion: The "Fungus Among Us" conspiracy is largely unfounded. While fungi can contribute to chronic wounds, bacteria are typically the primary culprits. Silicon nitride may offer some benefits in reducing microbial load, but it is unlikely to be a miracle cure for all chronic wound infections. A comprehensive approach that addresses the underlying causes of chronic wounds, including factors such as blood flow, immune function, and infection control, is essential for effective treatment.
Bacteria and Fungi are a major issue for wound care leading to chronic wounds. Yet Silicon Nitride kills various bacteria and fungi which means the material embedded in wound care applicators could significantly reduce these problems.
These exact problems are seen in the catheter industry as well and thus both industries need effective anti bacterial/fungal products.
Quote Sources:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874004/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258325/
========================================
Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
High Trading Volume:
Market Volatility: Periods of heightened market volatility or significant news events can often lead to increased trading activity. Without specific evidence of manipulation, attributing the high volume solely to a conspiracy is premature.
Institutional Interest: Institutions may have been interested in entering or exiting positions in SINT, leading to a surge in volume.
Retail Investor Enthusiasm: Positive news or developments related to SINT could have attracted retail investors, contributing to the volume.
Dilution via ATM:
Capital Raising: Companies often use ATM offerings to raise capital for growth, research and development, or debt repayment. This is a common corporate strategy, not necessarily a manipulative tactic.
Investor Protection: While the theory suggests that dilution was meant to protect existing shareholders, it's equally possible that the company was seeking to strengthen its financial position to better weather potential market downturns.
Market Dynamics: The timing of the dilution might have been influenced by market conditions, such as interest rates or investor sentiment.
Scientific Advancements in Silicon Nitride:
Legitimate Research: The research cited in Section 2 highlights the promising potential of silicon nitride in various medical applications. This is a well-established scientific fact, not a conspiracy theory.
Industry Trends: The shift towards innovative biomaterials like silicon nitride is a natural progression in the medical field, driven by advancements in technology and research.
Conclusion:
While it's understandable to be cautious about unusual market activity, the conspiracy theory presented lacks concrete evidence and relies on speculation. The high volume and ATM dilution can be explained by various factors, including market dynamics, investor behavior, and company strategies. The scientific advancements in silicon nitride, on the other hand, are supported by extensive research and industry trends.
To effectively debunk conspiracy theories, it's essential to rely on facts, logic, and scientific evidence. By examining the available information objectively, we can avoid falling victim to unfounded speculation and make informed decisions about investments.
Seriously how does no one think its odd that there was so much volume on the 9th for so few new shares? I speculated before that the volume was done in part to ensure shares went to where they wanted while disguising what was going on. Xena any ideas?
68m volume for maybe 400+k plus new shares as another 200k or so occurred on the 28th.
Debunking the Conspiracy Theory:
The theory suggests Sintx is hiding their involvement in the 3D printing webinar with Prodways. Here's why it's likely not true:
Joint Announcement: Both companies issued a press release on September 20th announcing the webinar, not just Prodways on August 28th. This indicates a coordinated effort.
Webinar Focus: The focus of the webinar is on "Innovations in Ceramic Manufacturing." While Sintx might not have a dedicated registration page, their expertise in ceramic materials aligns well with the topic. Their absence from the registration might simply be due to Prodways handling that aspect.
Collaboration Benefits: The press release highlights the benefits of the collaboration. It leverages the strengths of both companies: Prodways' printer expertise and Sintx's material science. This suggests a genuine partnership, not one where Sintx is hiding involvement.
Stock Price Fluctuations:
Stock prices can be volatile and react to various factors beyond just company news. Here are some possibilities:
Market Conditions: Overall market sentiment can affect stock prices. Even positive news might not translate to a rise if the broader market is experiencing a downturn.
Profit Taking: Some investors might sell their shares after positive news to lock in profits, causing a temporary dip.
Conclusion:
The evidence suggests a genuine collaboration between Sintx and Prodways for the 3D printing webinar. The stock price may be influenced by factors beyond just the announcement.
Speaking of partnership, Sintx and Prodways (R&D manufacturing partnership) are conducting a webinar on the future of 3D printing. Prodways posted the news back on August 28th. Sintx waited until last minute it seems. Also i couldnt find where to register via Sintx website so im including Prodways link for those that are interested.
Prodways and SINTX Announce Joint Webinar Stay Ahead of the Curve: “Innovations in Ceramic Manufacturing: The Role of 3D Printing”
1. Partnerships Don't Equal Conspiracy
The theory suggests Sintx's partnerships with various companies are evidence of a hidden agenda. However, partnerships are common business practice. Companies collaborate to leverage each other's expertise and resources to enter new markets or develop new products.
For example, Sintx's collaboration with Zimmer Biomet, a medical device company, makes perfect sense. Sintx's silicon nitride (Si3N4) technology could be valuable for developing stronger, biocompatible implants. Similarly, collaborations with Cardinal Health (PPE) and companies in wound care and catheters align with Sintx's material's potential applications.
2. Lack of Evidence for Nefarious Intent
The theory jumps from partnerships to the conclusion that Sintx is planning something malicious without any evidence. Having the capability to enter a market (e.g., condoms) doesn't imply a secret plan for world domination.
3. Focus on Potential, Not Guaranteed Success
The theory highlights the potential market size for Si3N4 applications but ignores the challenges of real-world implementation. Sintx might face regulatory hurdles, technical difficulties, or competition in these markets.
4. Unrealistic Revenue Projections
The hypothetical scenario of $811 million in yearly revenue through licensing assumes an unrealistic 5% market penetration across all mentioned sectors. New technologies often take time for widespread adoption.
In Conclusion
Sintx's partnerships are likely just smart business strategies. The claims about a hidden agenda lack evidence and rely on speculation. The potential market size for Si3N4 applications is promising, but successfully entering those markets is a different story.
This is precisely why their partnerships are so important! We know theyve been working with Morgan Ceramics. We know NP Aerospace was spun off from Morgan after Sintx was working with Morgan and that Sintx began its foray into the armor market with the help of NP Alum Donald Bray who left Morgan with the divestment of NP.
Claim 1: "Looking at the IP, its market size, I say they've created significant value for shareholders."
"Ah, yes, the magical world of IP. Where ideas are worth more than gold, and patents are like winning lottery tickets. Just because they have something doesn't mean they've done anything with it. Perhaps they've invented a new way to make invisible ink for invisible contracts."
Claim 2: "They are trying to create significant value for shareholders but still have not acquired shares."
"That's like a chef saying they're making a delicious meal but refusing to eat any of it. Perhaps they're saving it for a very special occasion, like the day their shares finally reach the moon."
Claim 3: "As to what exactly is going on between Sintx and NP Aerospace..."
"Oh, you know, just a casual business relationship between two companies with absolutely no connection to each other. It's totally coincidental that they're working in the same industry, at the same time, and with the same people. Must be a sign of the apocalypse."
Overall, these claims seem to be based on speculation and assumptions rather than concrete evidence. While it's always possible for a company to create significant value, it's important to base our judgments on facts and not just wishful thinking.
Looking at the IP, its market size, I say they've created significant value for shareholders. As that value is not cureently reflected in the shareprice they need to figure out a way to unlock it.
They are trying to create significant value for shareholders but still have not acquired shares. Odd no?
As to what exactly is going on between Sintx and NP Aerospace, i can only speculate. I just do not see it as a coincidence that Sintx was working with Morgan before NP was sold off and that NP spin off occurred relatively same timeframe as Sintx becoming Sintx. Not to mention Sintx sudden foray into armor market syncing with NP Aerospace main book of business. Its just logical they are strategic partners. What that will lead to remains to be seen.
Pagers and walkie talkies exploding in Lebanon , after electronic devices turn into bombs. Could this be caused by Geomagnetic unrest ? may the hutchinson effect ? A solar storm ? Boston745 any thought ? also could Sintx technologies have prevented this ?
As always, time will tell with this one. Unfortunately, if it is 'as always', it won't bode well for shareholders.
“We are pleased to have completed this successful capital raise, which not only strengthens our balance sheet but also allows us to focus on accelerating our growth initiatives,” said Eric K. Olson, President and CEO of SINTX Technologies, Inc. “This infusion of capital provides us with the financial resources necessary to fuel ongoing projects and reinforces our ability to deliver on our strategic objectives, ultimately creating significant value for our shareholders.”
Translation: we are pleased to inform ourselves that we can continue our bloated salaries with a word salad to the public. As you all can see, nothing of actual substance is in our announcement. Thank you once again for trusting us with your hard earned money. We in turn WILL continue to use that money as always...to benefit management!
A special note to those who invested in this recent offering and now see their stock at close to 30% lower: Better luck next time!
Debunking the Conspiracy Theory about SINTX Stock
Here's a breakdown addressing each point of the conspiracy theory about SINTX stock:
1. High Volume for Low Share Offering:
Explanation: Sometimes high volume can occur with a relatively small offering due to institutional investors placing large orders. This can happen for various reasons, like portfolio rebalancing or taking advantage of a perceived price discrepancy.
Debunking: The theory assumes the high volume was unusual or suspicious. However, it's possible there was legitimate institutional interest in SINTX at that time.
2. Dark Pool Trading:
Explanation: Dark pools are alternative trading venues where orders are not publicly displayed. They can be used to execute large trades without impacting the market price significantly.
Debunking: While dark pool trading can be opaque, it's not necessarily indicative of manipulation. It could simply be a way for institutions to buy or sell large quantities of shares without affecting the publicly displayed price.
3. Connection to NP Aerospace News:
Explanation: There's likely no connection between SINTX's activity and NP Aerospace news. The inclusion of the NP Aerospace news link seems unrelated and irrelevant to the alleged manipulation of SINTX stock.
4. Irrelevant Analogy and Personal Anecdote:
Debunking: The analogy about the squirrel and the Rubik's Cube, along with the personal story, don't provide any evidence to support the conspiracy theory. They seem like attempts to distract from the lack of concrete evidence.
Overall:
The provided information doesn't substantiate the claim of stock manipulation. High volume, dark pool trading, and institutional activity can all have legitimate explanations in the stock market. It's crucial to rely on factual data and financial analysis to assess a company's stock performance, not speculation.
Volume of 68m shares for up to 600k new shares priced at $5.23 average. OS is now 1.3m meaning the 9th saw 52x OS trade that day. That sure was alot of volume for so few shares and 97% of it was traded via dark pool. They were definitely trying to hide what was going on that day.
https://ir.sintx.com/news-events/press-releases/detail/237/sintx-announces-completion-of-3-1-million-atm-equity
NP Aerospace had a good week plus.
https://npaerospace.com/news/
========================================
"Given the divine mission to spread the gospel of conspiracy theories and geo-whatever, it's high time to send in the clown. The absurdist agent, a master of the ridiculous, will turn their grand delusions into a comedy of errors. Watch as they try to convince the world they're a prophet, only to end up as the butt of the joke. It's like watching a squirrel try to solve a Rubik's Cube – cute, but ultimately pointless."
And speaking of the absurd, let's not forget about SintX Technologies, a company so ridiculous it could be a plot point in a Monty Python sketch."
So, let's break down this wild theory about a "specialized disinformation agent" whose sole purpose is to... well, be absurd. It's like a real-life plot twist from a late-night comedy sketch.
Point 1: The "Unrelenting Shadow of Doubt"
The idea that this "absurdist" can somehow cast doubt on everything by being absurd is like saying a clown can make a serious debate about quantum physics seem silly. Sure, they might be funny, but it doesn't invalidate the science.
Point 2: The "Court Jester" Act
If this "absurdist" is so good at manipulating public opinion, why is he still a "court jester"? Shouldn't he be running a global empire from his secret lair? Or at least be on a reality TV show?
Point 3: The "Wild Assertions and False Data"
This is the funniest part. If someone is making obviously false statements, isn't that a pretty clear sign that they're not trying to manipulate anyone? They're just being silly.
Point 4: The "Self-Humiliation Rituals"
I guess this is supposed to make him seem more believable, like he's sacrificing his dignity for the greater good. But it mostly just makes him seem like someone who needs a hug.
In conclusion, this "absurdist agent" theory is a bit of a stretch. It's like trying to explain a magician's trick by claiming they're actually a secret agent from another dimension. While it might be entertaining for a while, it's ultimately more likely that people are just being themselves, whether that means being funny, serious, or a little bit weird.
*Imagine a world where SINTX technologies have advanced so far that they can be used to create a "smooth operator" skin cream. The cream is so effective that it not only reduces hair growth but also creates a silky-smooth surface on the skin.
One day, a man named Dave, who has always struggled with unwanted hair, decides to try the new cream. After applying it to his testicles, he notices a dramatic difference within a few hours. His testicles are now so smooth that they feel like polished marble.
Excited about his newfound smoothness, Dave decides to show off his new look at the beach. As he's sunbathing, a seagull swoops down and mistakes his testicles for a giant egg. The seagull attempts to roll the "egg" away, causing Dave to jump up in surprise.
From that day forward, Dave is known as the "Smooth Operator" of the beach, and his testicles become a local legend.
The future of SintX remains extremely strong and those shareholders who have faith in god will be handsomely rewarded.
Debunking the Conspiracy Theory: The Bacteriostatic Behavior of Silicon Nitride
The Conspiracy Theory:
The theory posits that silicon nitride (Si3N4) has inherent bactericidal and antifungal properties due to its surface characteristics, including submicron-topography, negative charging, and chemical interactions that produce peroxynitrite.
The Scientific Counterargument:
While silicon nitride is indeed a promising material for various biomedical applications, the claim that it has intrinsic antimicrobial properties is a gross oversimplification and potentially misleading. Here's why:
1. Surface Effects are Not Sufficient:
Submicron-topography: While surface roughness can influence bacterial adhesion, it's not a direct antimicrobial mechanism. Bacteria can adapt to various surface topographies.
Negative charging: Negative surface charges can repel bacteria, but this effect is not universally observed and can be overcome by bacterial surface modifications.
Peroxynitrite formation: While peroxynitrite is a potent oxidizing agent, its formation from Si3N4 interactions is speculative and would likely require specific conditions that may not be present in all environments.
2. Hydrolysis and Ammonia Production:
Hydrolysis: While silicon nitride can hydrolyze in aqueous environments, the rate and extent of hydrolysis depend on factors like pH, temperature, and the specific composition of the material.
Ammonia production: Ammonia can indeed have antimicrobial properties, but its concentration and release rate from Si3N4 would need to be carefully controlled to ensure efficacy without causing toxicity.
3. Material Composition and Manufacturing:
Impurities: The presence of impurities or contaminants in silicon nitride can significantly influence its surface properties and biological interactions.
Manufacturing processes: The specific manufacturing methods used to produce silicon nitride can affect its microstructure, surface chemistry, and potential antimicrobial activity.
4. Complex Biological Interactions:
Bacterial strains: The antimicrobial activity of a material can vary depending on the specific bacterial strain and its virulence factors.
Biofilm formation: Biofilms are complex communities of microorganisms that can be difficult to eradicate, and their interactions with materials are influenced by multiple factors.
Conclusion:
While silicon nitride is a promising biomaterial with potential applications in various medical devices, its antimicrobial properties are likely not solely due to its intrinsic surface characteristics. The observed bactericidal and antifungal effects may be influenced by a combination of factors, including the specific composition of the material, environmental conditions, and the interactions with microorganisms. Further research is needed to fully understand the mechanisms underlying the antimicrobial activity of silicon nitride and to optimize its use in biomedical applications.
Bacteriostatic behavior of surface modulated silicon nitride in comparison to polyetheretherketone and titanium
SintX is a fake it , till you make it scam - designed to fleece shareholders of there money. Here is why :
Potential Red Flags:
Overly ambitious promises: Sintx Technologies may have made grandiose claims about their technology's capabilities, potential market impact, and rapid growth.
Lack of transparency: The company might have been reluctant to disclose key details about its operations, financials, or product development.
Reliance on hype: Sintx Technologies may have heavily relied on marketing and public relations to create a positive image, rather than focusing on delivering a substantial product or service.
Limited tangible achievements: Despite the hype, the company may have struggled to demonstrate concrete milestones or tangible results.
1. Si3N4 as a Miracle Cure
Scientific skepticism: While Si3N4 has shown promise in certain applications, claiming it can "kill most bacteria and at least the most prevalent fungi" without further research and testing is premature. It's essential to conduct rigorous scientific studies to understand its efficacy, potential side effects, and compatibility with various materials.
Regulatory hurdles: Approving new medical technologies, especially those with antimicrobial properties, involves stringent regulatory processes. The FDA and other health authorities have strict guidelines to ensure safety and effectiveness. It's unlikely that any product could be rushed to market without thorough testing and documentation.
2. WWIII and Pandemic Predictions
Unfounded speculation: Predicting the occurrence of major world events like a third world war or a pandemic is highly speculative and often based on fear-mongering. While it's prudent to be prepared for unforeseen challenges, basing business decisions on such uncertain and unproven predictions is risky.
Solar Extrema and Pandemics: The claim that pandemics are connected to solar extrema lacks scientific evidence. There's no established causal link between solar activity and the emergence of infectious diseases. Such correlations are often coincidental and can be misleading.
3. Sintx, Zimmer Biomet, and IP
Business motivations: While it's true that companies often seek to diversify their product portfolios, suggesting that Zimmer Biomet would want Sintx's IP primarily due to potential war or pandemic-related benefits is overly simplistic. There are numerous factors influencing corporate decisions, including market demand, technological advancements, and competitive landscape.
Impact on business: While pandemics and wars can undoubtedly disrupt businesses, it's important to note that many companies have shown resilience and adaptability in the face of such challenges. By implementing appropriate strategies and contingency plans, businesses can mitigate the negative impacts and capitalize on opportunities.
Conclusion
The claims presented in the conspiracy theories are largely unsubstantiated and based on speculative assumptions. While it's reasonable to explore potential applications of Si3N4 in wound care and catheter materials, it's crucial to approach such developments with a scientific and evidence-based perspective. It's also important to avoid relying on fear-mongering and unfounded predictions to guide business decisions. By maintaining a balanced and informed approach, we can better assess the potential benefits and risks associated with new technologies and market trends.
Those problems present an enormous opportunity for Sintx and its partner(s) in the wound care/catherter markets. Imbuing wound care materials with Si3N4 will kill most bacteria and at least the most prevalent fungi like Candida. Coating catheters should do the same thing. However these things will take time to get to market with more testing and FDA submissions required. Thus its past-time for Sintx partner(s) in these two markets to step up, especially if WWIII is forthcoming.
If war is coming, along with another Pandemic, then its also past-time for PPE/protective apparel to get moving. If im correct about Solventum and Cardinal Health, then these two need to STEP-UP!
Global Catheter market = $55bn
Wound Care market = $22.25bn
Personal Protective Equipment market = $79.53 billion
Bill Gates says the world is facing two options: A ‘major war’ or another pandemic in less than 30 years
Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives.
Rebuttal: While it's certainly possible, Sintx's decades of research, extensive patent portfolio, and unique formulations give them a significant competitive advantage. Developing Si3N4-based medical devices from scratch would be a costly and time-consuming endeavor for larger companies, especially given the potential challenges in replicating Sintx's proprietary technology.
Counterargument 2: Competition could lead to fierce price wars.
Rebuttal: While competition can sometimes lead to price wars, Sintx's unique value proposition and strong intellectual property position it well to withstand such pressures. Their focus on niche markets and premium products can help differentiate their offerings and maintain profitability, even in a competitive environment.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.
Rebuttal: While partnerships don't guarantee success, they can significantly accelerate market penetration and reduce risks. Collaborating with established players like Solventum provides access to distribution channels, regulatory expertise, and clinical trials, which can be invaluable in bringing new medical technologies to market.
Counterargument 4: The wound care and catheter markets are not as difficult to enter.
Rebuttal: While these markets may seem less competitive than the ortho device industry, they still have their own unique challenges. Regulatory hurdles, reimbursement issues, and the need to demonstrate clinical efficacy and safety can be significant barriers to entry. Sintx's expertise and technology give them a competitive edge in these markets.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance.
Rebuttal: Sintx is actively addressing these concerns through ongoing research and development. They are continuously working to optimize their manufacturing processes and reduce costs, while also conducting long-term studies to evaluate the durability and performance of their Si3N4-based products.
Conclusion
The potential of Sintx's Si3N4-based medical devices is undeniable. Their unique technology, strong intellectual property, and strategic partnerships position them well for long-term success. While there are challenges to overcome, the potential benefits of these devices in terms of improved patient outcomes and reduced healthcare costs make them a compelling investment.
Counterargument 1: The occurrence of chronic wounds is a major global health issue.
Rebuttal: While chronic wounds are a significant problem, it's important to note that they are often associated with underlying health conditions such as diabetes and circulatory disorders. Addressing these underlying issues is crucial for effective wound healing, and the role of bacteria and fungi may be overstated.
Counterargument 2: Bacteria and Fungi are a major issue for wound care leading to chronic wounds.
Rebuttal: While bacteria and fungi can contribute to chronic wound infections, other factors such as inadequate blood flow, pressure, and poor nutrition are often more significant. The focus on microbial control may be diverting attention from these underlying causes.
Counterargument 3: These exact problems are seen in the catheter industry.
Rebuttal: While catheter-related infections are a concern, it's important to acknowledge that preventive measures such as proper insertion techniques and antiseptic care can significantly reduce the risk of microbial contamination. The emphasis on microbial control may be overshadowing the importance of these preventive strategies.
Counterargument 4: Silicon Nitride is a promising material for medical applications.
Rebuttal: While silicon nitride has shown promise in certain medical applications, it's important to consider the potential limitations and challenges. For example, the long-term biocompatibility of silicon nitride in various tissues and environments needs to be further evaluated. Additionally, the manufacturing and processing of silicon nitride can be complex and expensive, which may limit its widespread adoption.
Conclusion
While the potential benefits of silicon nitride in medical applications are promising, it's crucial to maintain a balanced perspective and consider the limitations and challenges associated with its use. Overemphasizing the role of microbial control in chronic wound healing and catheter infections may divert attention from other important factors, such as underlying health conditions and preventive measures.
Debunking your Conspiracy Theories:
Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives or partnerships.
Rebuttal: While it's possible that larger medical device companies are conducting research on Si3N4, Sintx has a significant head start due to its decades of dedicated research and development. Their extensive patent portfolio and unique formulations would create significant barriers to entry for competitors. Furthermore, licensing Sintx's technology would likely be a more efficient and cost-effective strategy than attempting to replicate their research from scratch.
Counterargument 2: Competition could lead to fierce price wars, delaying Sintx's profitability.
Rebuttal: The current market for Si3N4-based medical devices is relatively small, with Sintx as a dominant player. While potential competition could lead to price pressure, Sintx's strong intellectual property and unique product offerings would provide a competitive advantage. Moreover, the company's focus on niche markets and value-added products could help mitigate the impact of price competition.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.
Rebuttal: While there is no guarantee of product adoption, collaborations with established players like Solventum can provide significant benefits, such as access to distribution channels, regulatory expertise, and clinical trials. These partnerships can accelerate market penetration and increase the likelihood of commercial success.
Counterargument 4: The wound care and catheter markets are not as difficult to enter as the ortho device industry.
Rebuttal: While the wound care and catheter markets may be less competitive than the ortho device industry, they still present significant challenges. Sintx will need to demonstrate the clinical efficacy and cost-effectiveness of its Si3N4-based products in these markets to gain traction. Additionally, regulatory hurdles and reimbursement issues can also impact market entry and growth.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.
Rebuttal: Sintx is actively working to address these concerns. The company has been investing in research and development to improve the manufacturing process and reduce costs. Additionally, Sintx is conducting long-term studies to evaluate the durability and performance of its Si3N4-based products in real-world clinical settings.
Conclusion
While it's important to maintain a critical eye and consider potential risks, the evidence strongly supports the potential of Sintx's Si3N4-based medical devices to revolutionize the industry. The company's unique technology, strong intellectual property, and strategic partnerships position it well for long-term success.
While the potential of Sintx's technology is intriguing, let's explore some reasons why it might not translate to immediate dominance in the medical device space.
1. Partnerships Don't Guarantee Success:
Collaboration with companies like Solventum doesn't guarantee product adoption. Solventum might have other established suppliers or choose to develop their own Si3N4 technology.
Sintx relies on partners' expertise and marketing resources for product success. If a partner decides not to fully commit, it could stall product development or limit market reach.
2. Sintx Isn't the Only Player:
Existing medical device giants might have their own Si3N4 research initiatives or partnerships with other companies.
Competition could lead to fierce price wars, delaying Sintx's profitability.
3. Regulatory Hurdles:
Getting new medical devices (especially with novel materials) approved by the FDA can be a lengthy and expensive process.
Delays in regulatory approval could postpone Sintx's entry into these lucrative markets.
4. Unproven Advantages:
While research indicates the potential of Si3N4, Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.
Switching to new materials requires strong clinical data and surgeon buy-in, which could take time.
5. Legal Concerns:
The claim that Sintx has "over 100 patents pending" might not fully address the issue of competition.
Other companies could develop workarounds or alternative materials that don't infringe on Sintx's patents.
Alternative Considerations:
Investigate the specific terms of Sintx's partnerships and their commitment to developing Si3N4 products.
Analyze the competitive landscape in each potential market Sintx is targeting.
Research the current regulatory environment for Si3N4-based medical devices.
A Word of Caution:
The quote from Dr. Bal about large companies acquiring smaller ones "to de-risk IP" is a possibility, but not a guarantee. Many smaller companies remain independent for years without acquisition.
Remember, the medical device market is highly regulated and competitive. While Sintx presents exciting technology, it may face a long and challenging path to becoming a dominant player.
All three markets mentioned here from Jan presentation are markets that Solventum sells products in.
https://www.youtube.com/watch?v=j94SgeyCh3M
(AMDA) Amedica Corp. - NASDAQ
RECENT NEWS
https://www.youtube.com/watch?v=hxbj7Sq7W94
https://www.youtube.com/watch?v=j94SgeyCh3M
https://www.youtube.com/watch?v=KbU47COpXx8
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |